<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font18 { font-size : 18; } .font25 { font-size : 25; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font31 { font-size : 31; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font31">patients </span>
   <span class="font25">hepatitis </span>
   <span class="font25">HBV </span>
   <span class="font18">reactivation </span>
   <span class="font18">viral </span>
   <span class="font18">screening </span>
   <span class="font16">haematological </span>
   <span class="font16">(.%) </span>
   <span class="font15">antiviral </span>
   <span class="font15">EAS </span>
   <span class="font15">receiving </span>
   <span class="font15">risk </span>
   <span class="font15">{border-style </span>
   <span class="font14">chronic </span>
   <span class="font14">rate </span>
   <span class="font14">virus </span>
   <span class="font14">prophylaxis </span>
   <span class="font14">px;} </span>
   <span class="font14">#ffffff;} </span>
   <span class="font14">positive </span>
   <span class="font13">alert </span>
   <span class="font13">data </span>
   <span class="font13">HCV </span>
   <span class="font13">testing </span>
   <span class="font13">treatment </span>
   <span class="font12">anti-HBc-positive </span>
   <span class="font12">electronic </span>
   <span class="font12">lymphoma </span>
   <span class="font12">markers </span>
   <span class="font12">patients. </span>
   <span class="font12">study </span>
   <span class="font12">cases </span>
   <span class="font12">patients, </span>
   <span class="font12">treated </span>
   <span class="font12">HBsAg </span>
   <span class="font12">anti-HBc </span>
   <span class="font12">myeloid </span>
   <span class="font12">previously </span>
   <span class="font12">according </span>
   <span class="font12">clinical </span>
   <span class="font12">impact </span>
   <span class="font12">infection </span>
   <span class="font12">leukemia </span>
   <span class="font12">number </span>
   <span class="font12">prescription </span>
   <span class="font12">px; </span>
   <span class="font12">resolved </span>
   <span class="font12">therapy </span>
   <span class="font12">{font-family </span>
   <span class="font11">DNA </span>
   <span class="font11">anti-HCV </span>
   <span class="font11">avoided </span>
   <span class="font11">chemotherapy </span>
   <span class="font11">font-size </span>
   <span class="font11">inhibitors </span>
   <span class="font11">malignancies </span>
   <span class="font11">n(%) </span>
   <span class="font11">reported </span>
   <span class="font11">undergoing </span>
   <span class="font11">(). </span>
   <span class="font11">Hepatitis </span>
   <span class="font11">anti-CD-containing </span>
   <span class="font11">diagnosed </span>
   <span class="font11">double; </span>
   <span class="font11">estimated </span>
   <span class="font11">including </span>
   <span class="font11">kinase </span>
   <span class="font11">reactivation. </span>
   <span class="font11">reactivations </span>
   <span class="font11">regimens </span>
   <span class="font11">therapy. </span>
   <span class="font11">tyrosine </span>
   <span class="font11">use </span>
   <span class="font11">year </span>
   <span class="font11">HBsAg, </span>
   <span class="font11">HBsAg-positive </span>
   <span class="font11">However, </span>
   <span class="font11">anti-HBc, </span>
   <span class="font11">anti-HBs </span>
   <span class="font11">associated </span>
   <span class="font11">baseline </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">data. </span>
   <span class="font11">detectable </span>
   <span class="font11">drugs </span>
   <span class="font11">follicular </span>
   <span class="font11">included </span>
   <span class="font11">led </span>
   <span class="font11">linked </span>
   <span class="font11">low </span>
   <span class="font11">multiple </span>
   <span class="font11">myeloma </span>
   <span class="font11">panel </span>
   <span class="font11">patient </span>
   <span class="font11">physicians </span>
   <span class="font11">prescribed </span>
   <span class="font11">prophylaxis. </span>
   <span class="font11">received </span>
   <span class="font11">results </span>
   <span class="font11">solid; </span>
   <span class="font11">specific </span>
   <span class="font11">status </span>
   <span class="font11">test </span>
   <span class="font11">tyrosine-kinase </span>
   <span class="font11">underlying </span>
   <span class="font11">unknown </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(%) </span>
   <span class="font11">(Fig. </span>
   <span class="font11">Commons </span>
   <span class="font11">Creative </span>
   <span class="font11">Department, </span>
   <span class="font11">EAS. </span>
   <span class="font11">Hepatology </span>
   <span class="font11">March, </span>
   <span class="font11">Number </span>
   <span class="font11">Table </span>
   <span class="font11">Vall </span>
   <span class="font11">bold </span>
   <span class="font11">carried </span>
   <span class="font11">case </span>
   <span class="font11">cohort, </span>
   <span class="font11">completed </span>
   <span class="font11">courier; </span>
   <span class="font11">did </span>
   <span class="font11">d’Hebron </span>
   <span class="font11">em; </span>
   <span class="font11">follow-up </span>
   <span class="font11">hematological </span>
   <span class="font11">hepatitis, </span>
   <span class="font11">higher </span>
   <span class="font11">immunosuppressive </span>
   <span class="font11">important </span>
   <span class="font11">individuals </span>
   <span class="font11">infection, </span>
   <span class="font11">large </span>
   <span class="font11">liver </span>
   <span class="font11">lower </span>
   <span class="font11">new </span>
   <span class="font11">patient’s </span>
   <span class="font11">potential </span>
   <span class="font11">prescribed. </span>
   <span class="font11">prevalence </span>
   <span class="font11">prophylaxis, </span>
   <span class="font11">provided </span>
   <span class="font11">pt;} </span>
   <span class="font11">reactivation, </span>
   <span class="font11">receive </span>
   <span class="font11">tested </span>
   <span class="font11">using </span>
   <span class="font11">virological </span>
   <span class="font11">years, </span>
  </p>
 </body>
</html>
